IDYA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
8.9M
+35.0%
6.6M
-39.7%
10.9M
-94.8%
207.8M
0
Cost of Revenue
0
0
0
0
0
Gross Profit
8.9M
+35.0%
6.6M
-39.7%
10.9M
-94.8%
207.8M
0
Operating Expenses
131.1M
+13.9%
115.1M
+9.2%
105.4M
+6.1%
99.4M
+11.9%
88.8M
R&D
108.7M
+13.5%
95.7M
+10.5%
86.6M
+4.3%
83.0M
+11.8%
74.2M
SG&A
22.5M
+15.9%
19.4M
+2.8%
18.8M
+15.0%
16.4M
+12.4%
14.6M
Operating Income
-122291000
-12.7%
-108544000
-14.8%
-94570000
-187.2%
108.5M
+222.1%
-88806000
EBITDA
-121603000
-12.7%
-107856000
-14.9%
-93849000
-186.0%
109.1M
+223.9%
-88088000
Net Income
-112452000
-14.1%
-98539000
-18.3%
-83273000
-169.8%
119.2M
+253.9%
-77491000
EPS (Basic)
$-1.22
-9.9%
$-1.11
-18.1%
$-0.94
-169.6%
$1.35
+253.4%
$-0.88
EPS (Diluted)
$-1.22
-9.9%
$-1.11
-16.8%
$-0.95
-171.4%
$1.33
+251.1%
$-0.88
Shares (Diluted)
92.1M
+3.8%
88.7M
+1.5%
87.4M
-2.5%
89.7M
+1.4%
88.5M
IDEAYA Biosciences (IDYA) โ€” Financials